Loading organizations...
Key people at Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, that discovers, develops, and commercializes RNA interference therapeutics to silence disease-causing genes for rare genetic, cardio-metabolic, and central nervous system conditions. The publicly traded enterprise operates with a market capitalization exceeding $35 billion and generates over $1.8 billion in annual revenue from its portfolio of commercially approved medicines. Supported by more than $7.5 billion in total equity and raised capital, the organization employs over 2,000 people globally to advance its clinical pipeline and global commercialization efforts. Additionally, the firm maintains strategic research and licensing partnerships with major pharmaceutical corporations including Sanofi and Regeneron, while supplying healthcare providers with targeted prescription drugs like Onpattro and Amvuttra. Alnylam Pharmaceuticals was founded in 2002 by Christoph Westphal, Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore.
Alnylam Pharmaceuticals is a biopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat genetically defined diseases, particularly rare and common conditions affecting the liver and beyond.[2][3][4] Founded in 2002, it has evolved into a fully integrated company with over 2,000 employees worldwide, three to five approved products including Onpattro (patisiran), Amvuttra (vutrisiran), Givlaari (givosiran), Oxlumo (lumasiran), and Leqvio (inclisiran), and a robust pipeline targeting genetic medicines, cardio-metabolic, and other strategic therapeutic areas (STArs).[3][6] Alnylam serves patients with debilitating diseases by addressing unmet needs through infrequent, low-volume subcutaneous dosing, potent durability, and room-temperature stability, driving growth via its "P5x25" strategy for sustainable innovation and leadership by 2025.[2][3]
The company solves the challenge of gene silencing in humans, rooted in Nobel Prize-winning RNAi science, with early revenue reaching $2.25 billion and collaborations with giants like Sanofi, Roche, and Novartis fueling expansion.[1][4][6]
Alnylam traces its roots to a 1999 paper by Nobel Laureate Phillip Sharp, which demonstrated RNAi—using double-stranded RNA to silence genes in mammalian cells—sparking the vision for human therapeutics.[1] In 2002, Sharp co-founded the company in Cambridge, Massachusetts, with scientists David Bartel, Phillip Zamore, Thomas Tuschl, bioentrepreneur Paul Schimmel, and investors; John Maraganore joined as founding CEO, renaming it Alnylam from Precision Therapeutics.[1][4][5]
Early milestones included a 2003 merger with Ribopharma AG and $24.6 million funding, followed by a $331 million Roche deal in 2007 amid RNAi hype.[1][4] Delivery challenges dominated the first decade, with over 80% of R&D focused on it, testing dozens of systems before breakthroughs like GalNAc conjugates and lipid nanoparticles (LNPs).[1][6] Pivotal 2013 Phase I data showed protein reduction via intravenous/subcutaneous dosing, validating the platform and attracting partners like Sanofi.[4]
Alnylam's edge lies in its RNAi platform, transforming Nobel science into approved medicines with unique attributes:
These factors position Alnylam ahead in RNAi commercialization over competitors still in discovery.[1][2]
Alnylam rides the RNAi therapeutics wave, a post-Nobel revolution in gene silencing that shifts treatment from proteins to root genetic causes, timing perfectly with advances in delivery post-2010s hurdles.[1][2] Market forces like rising rare disease prevalence, demand for precision meds, and biotech funding favor it, especially as RNAi proves viable beyond mRNA vaccines.[3][6]
It influences the ecosystem by validating RNAi (e.g., spin-offs like Regulus, collaborations expanding to vaccines/neurodegeneration), lowering barriers for followers, and driving biopharma toward platform-based innovation over one-off drugs.[1][4] As a Cambridge hub player, Alnylam accelerates the shift to sustainable biotech models amid aging populations and genetic insights.[2][6]
Alnylam is on track to fulfill its P5x25 vision by 2025, expanding beyond liver to extra-hepatic tissues like heart and muscle, with pipeline proof-of-concepts in rare/common diseases and revenue growth from approved drugs.[2][3][6] Trends like AI-aided discovery, combo therapies, and global access will shape it, potentially evolving into a multi-platform leader influencing RNAi adoption industry-wide.
This builds on its origin as RNAi pioneers, turning Sharp's 1999 insight into a new medicine class—proving bold science delivers for patients waiting for hope.[1][2]
Key people at Alnylam Pharmaceuticals.
